Location History:
- Seattle, WA (US) (2014)
- Gaithersburg, MD (US) (2017)
- San Diego, CA (US) (2020 - 2024)
Company Filing History:
7 out of 1,105 
2 out of 66 
1 out of 2,365 
Years Active: 2014-2025
Title: **Inventor Spotlight: Shile Zhang**
Introduction
Shile Zhang is an accomplished inventor based in San Diego, California, known for his significant contributions to the fields of biotechnology and genomics. Holding six patents to his name, Zhang's innovative work largely revolves around advancing methodologies in cancer research and diagnostics.
Latest Patents
Among his notable inventions, Zhang has developed a patent for "Systems and methods for determining microsatellite instability." This patent introduces techniques for assessing microsatellite instability in individual samples, even when matched sample data is unavailable. This process is pivotal in understanding the genetic alterations found in certain cancers. Additionally, he holds a patent for "Quantitative score of HLA diversity," which focuses on measuring HLA diversity in tumor DNA samples, enabling predictions regarding a patient's response to immune checkpoint inhibitors.
Career Highlights
Zhang is currently associated with Illumina Corporation, a leader in genomic sequencing and analysis. His role involves leveraging cutting-edge technologies to enhance diagnostic capabilities for various diseases. Through his innovative thinking and technical expertise, he has made strides in developing tools that are essential for personalized medicine.
Collaborations
Throughout his career, Zhang has collaborated with esteemed colleagues, including Kristina Kruglyak and Mengchi Wang. These professional partnerships have facilitated the sharing of ideas and fostered an environment of innovation, directly contributing to the success of their projects and patents.
Conclusion
Shile Zhang's innovative spirit and dedication to advancing biotechnology have made a significant impact in his field. With a robust portfolio of patents and a commitment to collaborative research at Illumina Corporation, he continues to push the boundaries of what is possible in cancer diagnostics and treatment strategies. His contributions not only enhance our understanding of genetic complexities but also pave the way for improved patient care and outcomes.